Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • YM 58483 (BTP2): Applied SOCE Blockade in Fibrosis Models

    2026-07-17

    YM 58483 (BTP2): Applied SOCE Blockade in Fibrosis Models

    Principle and Setup: Selective SOCE Inhibition for Fibrosis and Immune Modulation

    Store-operated calcium entry (SOCE) is a pivotal pathway regulating intracellular Ca2+ homeostasis in non-excitable cells, including lymphocytes and fibroblasts. Activation of SOCE channels—comprising highly Ca2+-selective CRAC channels and non-selective TRP channels—underlies processes from T cell activation to tissue fibrosis. YM 58483 (BTP2), supplied by APExBIO, is a potent and selective SOCE inhibitor, blocking both CRAC and TRP channel-mediated Ca2+ influx. As reported in the YM 58483 (BTP2), a store-operated Ca2+ entry (SOCE) blocker product information, this molecule exhibits an IC50 of ~17 nM for IL-2 inhibition, ensuring high sensitivity for signaling modulation.

    Recent advances, such as the reference study on salivary gland fibrosis, have spotlighted the ORAI2/JNK/NFAT1/TGF-β1 signaling axis as a key driver in post-irradiation tissue remodeling. Pharmacological blockade of SOCE with YM 58483 offers a targeted approach to dissecting these pathways, enabling researchers to control fibrogenic and immunomodulatory responses with precision.

    Step-by-Step: Enhanced Experimental Workflows Using YM 58483

    Integrating YM 58483 (BTP2) into experimental models streamlines both in vitro and in vivo workflows targeting calcium-dependent processes. Below is a protocol-enhanced overview for SOCE-driven fibrosis and immune signaling assays:

    Protocol Parameters

    • Compound preparation: Dissolve YM 58483 in DMSO at 90 mg/mL or ethanol at 50 mg/mL; prepare fresh working solutions for each experiment to ensure potency.
    • In vitro SOCE inhibition: Treat cells (e.g., primary fibroblasts or lymphocytes) with 0.03–1 μM YM 58483 for 30–120 minutes before stimulation (e.g., ionomycin or PHA) to block Ca2+ influx.
    • In vivo dosing: Administer YM 58483 at 2–10 mg/kg via intraperitoneal injection daily for 10–30 days when modeling post-irradiation fibrosis or immune modulation in murine models, following published schedules.

    For T cell activation assays, YM 58483 can be added 30 minutes prior to PHA or anti-CD3/CD28 stimulation, with downstream readouts including IL-2 production and NFAT-driven reporter activity. In fibrosis studies, especially those recapitulating radiation-induced tissue damage, pre-treatment and chronic administration protocols enable robust assessment of fibrogenic endpoints (e.g., collagen expression, TGF-β1 quantification, functional saliva output).

    Key Innovation from the Reference Study

    The recent landmark study demonstrated that ORAI2-mediated SOCE is essential for early-stage postirradiation salivary gland fibrosis. By applying YM 58483 as a selective SOCE inhibitor, researchers blocked the ORAI2/JNK/NFAT1 axis, significantly reducing fibrotic markers and restoring salivary flow to 84.61% of normal in irradiated mice. Notably, this pharmacological approach achieved pathway-specific modulation without detectable side effects, highlighting YM 58483’s value for both mechanistic interrogation and translational modeling.

    Practical assay implications include:

    • Targeted inhibition of the ORAI2/JNK/NFAT1 pathway, allowing specific dissection of TGF-β1-driven fibrogenesis.
    • Quantitative evaluation of SOCE-dependent endpoints (e.g., collagen, myofibroblast markers, functional tissue output) within 30 days post-irradiation.
    • Improved reproducibility and selectivity compared to less specific SOCE inhibitors (e.g., SKF96365).

    Advanced Applications and Comparative Advantages

    YM 58483 (BTP2) has redefined experimental control in both immune and fibrosis research. Its selectivity for CRAC and TRP channels enables focused interrogation of downstream NFAT-dependent gene expression, T cell activation, and fibrotic remodeling. For example, dose-dependent inhibition of IL-2 production and potent suppression of NF-AT-driven promoter activity have been repeatedly demonstrated, while sparing AP-1-driven gene expression, according to product literature and multiple workflow validations.

    The compound’s impact is further contextualized by existing reviews and practical guides:

    Compared to older or less selective SOCE inhibitors, YM 58483’s robust performance in both short-term signaling assays and chronic disease models makes it indispensable for dissecting Ca2+-dependent biology.

    Troubleshooting and Optimization Tips

    Achieving consistent results with YM 58483 (BTP2) relies on attention to compound preparation, timing, and endpoint selection:

    • Solubility challenges: Due to its insolubility in water, always dissolve YM 58483 in DMSO or ethanol at recommended concentrations. Vortex thoroughly and, if needed, sonicate briefly to ensure a clear solution.
    • Batch-to-batch consistency: Use freshly prepared stock solutions and avoid repeated freeze-thaw cycles; store aliquots at -20°C for short-term use as per supplier guidelines.
    • Minimize cytotoxicity: Titrate concentrations empirically; start with 0.03–0.1 μM for sensitive primary cells and scale up only as needed, monitoring cell viability in parallel with functional endpoints.
    • Assay timing: For acute signaling studies, pre-incubate cells with YM 58483 at least 30 minutes before stimulation. For chronic models, ensure daily dosing schedules are maintained to sustain SOCE inhibition.
    • Control treatments: Always include solvent controls (DMSO or ethanol) at matching concentrations to distinguish genuine effects from vehicle artifacts.

    Future Outlook: Toward Precision Fibrosis and Immune Modulation

    The emergence of YM 58483 as a precision tool for SOCE blockade heralds a new era in dissecting calcium signaling in both basic and translational research. The reference study not only validates the centrality of the ORAI2/JNK/NFAT1/TGF-β1 axis in radiation-induced fibrosis but also paves the way for targeted intervention in other Ca2+-driven pathologies. As evidence accumulates for the therapeutic potential of SOCE inhibition in immune-mediated and fibrotic diseases, YM 58483 is poised to remain a cornerstone for both discovery and preclinical modeling.

    For researchers seeking a validated, selective, and reproducible SOCE inhibitor, YM 58483 (BTP2), a store-operated Ca2+ entry (SOCE) blocker from APExBIO offers a best-in-class solution, backed by robust peer-reviewed data and a growing portfolio of experimental successes.